The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1196-1206

  Brunetti, Luigi ^a   Hermes DeSantis, Evelyn R ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Bile acid sequestrant; Colesevelam; Dyslipidemia; Hypercholesterolemia; Type 2 diabetes mellitus

Indexed keywords

COLESEVELAM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA; ALLYLAMINE; HYPOCHOLESTEROLEMIC AGENT;

ADD ON THERAPY; CLINICAL ASSESSMENT; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPEPSIA; FLATULENCE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; MEDICAL SOCIETY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION;

ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERCHOLESTEROLEMIA;

EID: 77954615014     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M728     Document Type: Review

References (77)

1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep 2008;56:1-120. www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-10.pdf
2. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-181. DOI 10.1161/CIRCULATIONAHA.108.191261
3. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78. DOI 10.1016/S0140-6736(05)67394-1
4. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results, I: reduction in incidence of coronary heart disease. JAMA 1984;251:351-64. DOI 10.1001/jama.251.3.351
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97. DOI 10.1001/jama.285.19.2486
6. Gerstein HC, Miller ME, Byington RP, et al. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59. DOI 10.1056/NEJMoa0802743
7. Patel A, MacMahon S, Chalmers J, et al. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72. DOI 10.1056/NEJMoa0802987
8. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39. DOI 10.1056/NEJMoa0808431
9. Montori VM, Fernandez-Basells M. Glycemic control in type 2 diabetes: time for an evidence based about-face? Ann Intern Med 2009;150:803-8. www.annals.org/content/150/11/803.full.pdf+html
10. Lehman R, Krumholz HM. Tight control of blood glucose in long standing type 2 diabetes. BMJ 2009;338:b800. DOI 10.1136/bmj.b800
11. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-90. DOI 10.1517/14656566.4.5.779
12. Davidson M, Hunninghake D, Olson T, et al. Colesevelam HCl (Welchol), a new, potent, well-tolerated, non-systemic, lipid lowering agent. Presented at: 12th International Symposium on Atherosclerosis, Stockholm, Sweden, June 25-29, 2000.
13. Insull W, Toth P, Mullican W, et al. Cholestagel, a novel, highly potent, polymeric bile acid sequestrant significantly lowers LDL cholesterol (abstract). J Am Coll Cardiol 2000;35:258A.
14. Shepherd J, Packard CJ, Bicker S, Lawrie TDV, Morgan HG. Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism. N Engl J Med 1980;302:1219-22. http://content.nejm.org/cgi/content/abstract/302/22/1219
15. Kuipers F, Murphy EJ. Effects of colesevelam HCl on bile acid kinetics. www.clinicaltrials.gov/ct2/show/NCT00476710?term = colesevelam+HCl&rank = 8 (accessed 2009 Sept 19).
16. Vella A. The effect of colesevelam hydrochloride (HCl) on disposition index and incretin concentrations in subjects with type 2 diabetes. www.clinicaltrials.gov/ct2/show/study/NCT00951899?term = colesevelam+HCl& recr = Open&rank = 2 (accessed 2009 Sept 19).
17. Corsini A, Windler E, Farnier M. Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Eur J Cardiovasc Prev Rehabil 2009;16:1-9. DOI 10.1097/HJR.0b013e32831215db
18. Beysen C, Deines K, Tsang E, et al. Colesevelam HCl improves glucose metabolism and increases plasma glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide concentrations in subjects with type 2 diabetes. Presented at: 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29-October 2, 2009.
19. Goldfine AB. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Curr Opin Cardiol 2008;23:502-11. DOI 10.1097/HCO.0b013e32830c6c37
20. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007;445:219-23. DOI 10.1038/nature05449
21. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 2007;74:338-43. DOI 10.1272/jnms.74.338
22. Davidson MH, Dillon MA, Jones PJ, et al. Colesevelam hydrochloride (cholestagel). A new potent bile acid sequestrant with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-900. DOI 10.1001/archinte.159.16.1893
23. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971-82. DOI 10.4065/76.10.971
24. Stein EA, Marais D, Szamosi T, et al. Colesevelam hydrochloride: efficacy and safety in pediatric patients with heterozygous familial hypercholesterolemia. J Pediatr 2009;156:231-6. http://Linkinghub.elsevier.com/ retrieve/pii/S002234760900804X
25. Roberts WC. The rule of 5 and the rule of 7 in lipid lowering by statin drugs. Am J Cardiol 1997;80:106-7. DOI 10.1016/S0002-9149(97)00298-1
26. Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004;38:1286-92. DOI 10.1345/aph.1D391
27. Spann SJ, Nutting PA, Galliher JM, et al. Management of type 2 diabetes in the primary care setting: a practice-based research network study. Ann Fam Med 2006;4:23-31. DOI 10.1370/afm.420
28. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dose statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14. DOI 10.1007/s10557-005-5686-z
29. Parris ES, Mohn LA, Lawrence DB, Long LA. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005;28:595-9. DOI 10.2337/diacare.28.3.595
30. Davidson MH, Toth P, Weiss S, et al. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol 2001;24:467-74. DOI 10.1002/clc.4960240610
31. Hunninghake D, Insull W, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis 2001;158:407-16. DOI 10.1016/S0021-9150(01)00437-3
32. Knapp HH, Schrott H, Ma P, et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001;110:352-60. DOI 10.1016/S0002-9343(01)00638-6
33. Bays HE, Davidson M, Jones MR, Abby SL. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 2006;97:1198-205. DOI 10.1016/j.amjcard.2005.11.039
34. Bays H, Rhyne J, Abby S, Lai YL, Jones M. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 2006;22:2191-200. DOI 10.1185/030079906X148436
35. Rivers SM, Kane MP, Busch RS, Bakst G, Hamilton RA. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 2007;13:11-6. http://aace.metapress.com/Link.asp?id=v1331178816n585v
36. Knopp RH, Tsunehara C, Retzlaff BM, et al. Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 2006;55:1697-703. DOI 10.1016/j.metabol.2006.08.013
37. Zema MJ. Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005;12:306-10. DOI 10.1097/01.mjt.0000155109. 69831.a3
38. McKenney J, Jones M, Abby S. Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 2005;21:1403-12. DOI 10.1185/030079905X59157
39. Moore A, Phan B, Challender C, Williamson J, Marcinova S, Zhao X. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol 2007;1:620-5. DOI 10.1016/j.jacl.2007.09.001
40. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22. DOI 10.1056/NEJMoa0907569
41. Davidson MH. The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review. Expert Opin Pharmacother 2007;8:2569-78. DOI 10.1517/14656566.8.15.2569
42. Staels B, Kuipers F. Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 2007;67:1383-92. DOI 10.2165/00003495-200767100-00001
43. Handelsman Y, Abby SL, Jin X, Donovan JM, Jones MR. Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med 2009;121:62-9. DOI 10.3810/pgm.2009.11.2078
44. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83. DOI 10.1016/j.clinthera.2007.01.003
45. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin. Arch Intern Med 2008;168:1975-83. DOI 10.1001/archinte.168.18.1975
46. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-84. DOI 10.2337/dc08-0283
47. Goldberg RB, Fonseca VA, Truitt K, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-40. DOI 10.1001/archinte.168.14.1531
48. Jones MR, Mudaliar S, Hernandez-Triana E, et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first line therapy in type 2 diabetes and colesevelam in prediabetes. Curr Med Res Opin 2009;25:2239-49. DOI 10.1185/03007990903126791
49. Jialal I, Abby SL, Misir S, Nagendran S. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. Metab Syndr Relat Disord 2009;7:255-8. DOI 10.1089/met.2009.0007
50. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New Engl J Med 2008;359:2195-207. DOI 10.1056/NEJMoa0807646
51. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and the lipid profile in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Endocr Prac 2010;16:53-63. DOI 10.4158/EP09146.OR
52. American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care 2009;32:S13-61. DOI 10.2337/dc09-S013
53. Ong JI, Cheung BM, Wong LY, et al. Prevalence, treatment, and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol 2008;18:222-9. DOI 10.1016/j.annepidem.2007.10.007
54. Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-67. DOI 10.3132/dvdr.2008.027
55. Package insert. Glucophage (meformin). Princeton, NJ: Bristol Myers Squibb, January 2009. http://packageinserts.bms.com/pi/pi-glucophage.pdf
56. Gervasio JM. Diarrhea and constipation. In: Tisdale JE, Miller DA, eds. Drug-induced disease: prevention, detection, and management. Bethesda, MD: American Society of Health-System Pharmacists, 2005.
57. Dunn CJ, Peters DH. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995;49:721-49. DOI 10.2165/00003495-199549050-00007
58. Simons WR, Hagan M. The cost effectiveness of adding colesevelam hydrochloride to metformin in patients with type 2 diabetes who have not achieved optimal glycemic control (abstract 320 1217-P). Presented at: 69th Annual Scientific Sessions of the American Diabetes Association, June 5-9, 2009. http://ww2.aievolution.com.
59. Carter D, Howlett HCS, Wiernsperger NF, Bailey CJ. Effects of metformin on bile salt transport by monolayers of human intestinal Caco-2 cells. Diabetes Obes Metab 2002;4:424-7. DOI 10.1046/j.1463-1326.2002.00223.x
60. Carter D, Howlett HCS, Wiernsperger NF, Bailey CJ. Differential effects of metformin on bile acid salt absorption from the jejunum and ileum. Diabetes Obes Metab 2003;5:120-5. DOI 10.1046/j.1463-1326.2003.00252.x
61. Puleston J, Morgan H, Andreyev J. New treatment for bile acid malabsorption. Gut 2005;54:441-2. DOI 10.1136/gut.2004.054486
62. Walters JRF, Tasleem AM, Omer OS, et al. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin Gastroenterol Hepatol 2009;7:1189-94. DOI 10.1016/j.cgh.2009.04.024
63. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-65. DOI 10.1016/j.cgh.2009.10.020
64. Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ. Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol 2004;97:167-72. DOI 10.1016/j.ijcard.2003.07.033
65. Rodbard H, Jellinger P, Davidson HA, et al. Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-59. www.aace.com/pub/pdf/GlycemicControlAlgorithm.pdf
66. Joslin Diabetes Center. Joslin Diabetes Center & Joslin Clinic clinical guideline for pharmacological management of type 2 diabetes 1/09/2009. www.joslin.org/Files/Clinical-Guidelines-for-Pharmacological-Management-of- Type2-Diabetes.pdf (accessed 2009 Nov 25).
67. Goldfine AB, Fonseca VA, Jones MR, Wang AC, Ford DM, Truitt KE. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010;42:23-30. DOI 10.1055/s-0029-1241195
68. Briggs GG, Freeman RK, Yaffe SJ, eds. Drugs in pregnancy and lactation. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2002.
69. Donovan JM, Stypinski D, Stiles MR, Olson TA, Burke SK. Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc Drugs Ther 2000;14:681-90. DOI 10.1023/A:1007831418308
70. Donovan JM, Kisicki JC, Stiles MR, Tracewell WG, Burke SK. Effect of colesevelam on lovastatin pharmacokinetics. Ann Pharmacother 2002;36:392-7. DOI 10.1345/aph.1A144
71. Jones MR, Baker BA, Mathew P. Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 2004;43:943-50. DOI 10.2165/00003088-200443130-00006
72. Kosoglou T, Statkevich P, Johnson-Levonas AO, et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-94. DOI 10.2165/00003088-200544050-00002
73. Weitzman SP, Ginsburg KC, Carlson HE. Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid 2009;19:77-9. DOI 10.1089/thy.2008.0312
74. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001;35:898-907. DOI 10.1345/aph.10263
75. Product information. Welchol (colesevelam hydrochloride). Parsippany, NJ: Daiichi Sankyo Inc., October 2009. www.welchol.com/pdf/Welchol-PI.pdf
76. Ito MK, Stolley SN. A matter of taste. Am J Health Syst Pharm 1999;56:80-1. www.ajhp.org/cgi/content/citation/56/1/80
77. Hanus M, Zhorov E. Bile acid salt binding with colesevelam HCl is not affected after suspension in common beverages. J Pharm Sci 2006;95:2751-9. DOI 10.1002/jps.20734